Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Total Debt (2016 - 2022)

Aptevo Therapeutics' Total Debt history spans 8 years, with the latest figure at $3.5 million for Q4 2022.

  • For Q4 2022, Total Debt fell 77.52% year-over-year to $3.5 million; the TTM value through Dec 2022 reached $3.5 million, down 77.52%, while the annual FY2022 figure was $3.5 million, 77.52% down from the prior year.
  • Total Debt for Q4 2022 was $3.5 million at Aptevo Therapeutics, down from $3.9 million in the prior quarter.
  • Across five years, Total Debt topped out at $25.2 million in Q3 2020 and bottomed at $3.5 million in Q4 2022.
  • The 5-year median for Total Debt is $19.2 million (2018), against an average of $15.7 million.
  • The largest annual shift saw Total Debt grew 27.87% in 2020 before it tumbled 77.52% in 2022.
  • A 5-year view of Total Debt shows it stood at $19.3 million in 2018, then grew by 3.03% to $19.9 million in 2019, then grew by 26.13% to $25.1 million in 2020, then crashed by 38.64% to $15.4 million in 2021, then crashed by 77.52% to $3.5 million in 2022.
  • Per Business Quant, the three most recent readings for APVO's Total Debt are $3.5 million (Q4 2022), $3.9 million (Q3 2022), and $4.4 million (Q2 2022).